Risk of serious ventricular arrhythmia and sudden cardiac death in a cohort of users of domperidone: a nested case-control study
Article first published online: 22 JUL 2010
Copyright © 2010 John Wiley & Sons, Ltd.
Pharmacoepidemiology and Drug Safety
Volume 19, Issue 9, pages 881–888, September 2010
How to Cite
Johannes, C. B., Varas-Lorenzo, C., McQuay, L. J., Midkiff, K. D. and Fife, D. (2010), Risk of serious ventricular arrhythmia and sudden cardiac death in a cohort of users of domperidone: a nested case-control study. Pharmacoepidem. Drug Safe., 19: 881–888. doi: 10.1002/pds.2016
- Issue published online: 25 AUG 2010
- Article first published online: 22 JUL 2010
- Manuscript Revised: 8 JUN 2010
- Manuscript Accepted: 8 JUN 2010
- Manuscript Received: 30 NOV 2009
- Johnson & Johnson Pharmaceutical Research and Development
Limited information from spontaneous reports and results of two case-control studies raised concern about the cardiotoxicity of oral domperidone therapy. This case-control study nested in a retrospective cohort evaluated the combined risk of serious ventricular arrhythmia (SVA) and sudden cardiac death (SCD) in users of domperidone compared with users of proton pump inhibitors (PPIs), or non-users of these medications.
A cohort of users of domperidone or a PPI from 1990 to 2005 was identified from existing electronic databases of Saskatchewan Health. Possible cases of SVA/SCD were identified using hospital discharge and vital statistics codes. SVA cases were validated by cardiologist review of abstracted hospital medical charts. Up to four controls were matched to each case by index date, year of birth, sex, and diabetes status. The odds ratio (OR) of current domperidone exposure relative to non-use or to current PPI exposure was estimated and adjusted for possible confounding variables using conditional logistic regression.
From 83 212 individuals in the exposure cohort we identified 1608 cases, 49 SVA and 1559 SCD (mean age 79.4 years, females 52.9%, diabetes 22.3%) and 6428 matched controls. The adjusted OR for SVA/SCD with current domperidone use compared with non-use was (1.59, 95%CI: 1.28–1.98), or compared with current PPI use was (1.44, 95%CI: 1.12–1.86). In stratified analyses adjusted ORs were numerically higher in males, older subjects, and non-diabetics.
The increased risk of SVA/SCD for current domperidone users remained after adjustment for multiple covariates. The risk may vary among subgroups of exposed individuals. Copyright © 2010 John Wiley & Sons, Ltd.